IOVANCE BIOTHERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.31 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-24
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $177.00K, a 67.99% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $2.31M, a 1202.82% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $177.00K, a 67.99% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $553.00K, a 96.86% decline from fiscal 2021.
- IOVANCE BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $17.62M, a 64.99% decline from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $2.31M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $177.00K derived: sum of 3 quarters · filed 2025-02-27 | $177.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $177.00K derived: sum of 2 quarters · filed 2024-11-07 | $177.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $177.00K 10-Q · filed 2024-08-08 | $177.00K 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $553.00K derived: sum of 3 quarters · filed 2024-02-28 | $553.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $553.00K derived: sum of 2 quarters · filed 2023-11-07 | $553.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $553.00K 10-Q · filed 2023-08-08 | $553.00K 10-Q · filed 2023-08-08 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $17.00M derived: sum of 2 quarters · filed 2023-02-28 | $17.62M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $17.00M 10-Q · filed 2022-11-03 | $17.62M 10-Q · filed 2022-11-03 | ||
| 2021-03-31 | $618.00K 10-Q · filed 2022-05-05 | $46.28M derived: sum of 2 quarters · filed 2022-05-05 | $50.95M derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $45.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $50.33M derived: sum of 2 quarters · filed 2022-02-24 | $50.33M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $4.67M 10-Q · filed 2021-11-04 | $4.67M 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.43M derived: sum of 2 quarters · filed 2021-02-25 | $4.09M derived: sum of 3 quarters · filed 2021-02-25 | $4.09M 10-K · filed 2021-02-25 |
| 2019-09-30 | $3.43M 10-Q · filed 2020-11-05 | $4.09M derived: sum of 2 quarters · filed 2020-11-05 | $4.09M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $667.00K 10-Q · filed 2020-08-06 | $667.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |